Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech, Inc. has announced progress in its preconditional privatisation by Fosun New Medicine, indicating the potential for a merger by absorption. The update follows the fulfillment of the required share threshold for the Potential Share Alternative Offer. The company is currently finalizing an announcement regarding its decision on whether to proceed with the offer.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.